Skin Inflammation - Pipeline Review, H2 2012

Description: Skin Inflammation – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Skin Inflammation - Pipeline Review, H2 2012', provides an overview of the Skin Inflammation therapeutic pipeline. This report provides information on the therapeutic development for Skin Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Inflammation. 'Skin Inflammation - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Skin Inflammation.
- A review of the Skin Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin Inflammation pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Skin Inflammation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Skin Inflammation pipeline depth and focus of Skin Inflammation therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Skin Inflammation Therapeutic Products under Development, Key Players in Skin Inflammation Therapeutics, Skin Inflammation Pipeline Overview, Skin Inflammation Pipeline, Skin Inflammation Pipeline Assessment

Contents:

2  List of Tables 7
   List of Figures 9
   Introduction 10
   REPORT COVERAGE 10
Cutanea Life Sciences 80
Action Pharma A/S 81
SWITCH Biotech LLC 82
Morria Biopharmaceuticals Plc 83
Maruho Co.,Ltd. 84
Pharis Biotec GmbH 85
Viromed Co., Ltd. 86
Celtic Pharmaceutical Holdings L.P. 87
EMS S.A. 88
Clarassance, Inc. 89
Skin Inflammation – Therapeutics Assessment 90
Assessment by Monotherapy Products 90
Assessment by Combination Products 91
Assessment by Route of Administration 92
Assessment by Molecule Type 95
Drug Profiles 98
GW870086 - Drug Profile 98
BMS-981164 - Drug Profile 100
MK52 - Drug Profile 101
MK51 - Drug Profile 102
MK50 - Drug Profile 103
SUN13834 - Drug Profile 104
Steroid DuraPeel - Drug Profile 105
NCX 1047 - Drug Profile 106
Toctino - Drug Profile 107
DD-1 - Drug Profile 109
AMG 157 - Drug Profile 110
CT327 - Drug Profile 111
PH-10 - Drug Profile 113
DPK-060 - Drug Profile 115
HL009 - Drug Profile 116
OC000459 - Drug Profile 117
LEO 29102 - Drug Profile 119
HYG-440 - Drug Profile 120
PYM60001 - Drug Profile 122
MRX6 - Drug Profile 123
DNK-333 - Drug Profile 124
IMD-0354 - Drug Profile 125
WBI-1001 - Drug Profile 126
TASS - Drug Profile 128
PBI-1308 - Drug Profile 129
ProtoCure Emulsion Cream - Drug Profile 130
AN2898 - Drug Profile 132
LAS41004 - Drug Profile 134
SMT D002 - Drug Profile 135
J607Y - Drug Profile 136
J775Y - Drug Profile 137
NF KappaB Decoy Oligo - Drug Profile 138
Mapracorat - Drug Profile 140
J555Y - Drug Profile 142
AP405 - Drug Profile 143
AN2728 - Drug Profile 144
NS-141 - Drug Profile 145
SWT01113 - Drug Profile 147
SWT05141 - Drug Profile 148
PAR-2 Program - Drug Profile 149
RTU-1096 - Drug Profile 150
Aminopterin - Drug Profile 151
Nanoliposomized Topical Agent - Drug Profile 152
LAS41003 - Drug Profile 153
LAS41002 - Drug Profile 154
Kineret - Drug Profile 155
DRM-02 - Drug Profile 156
Number of Products under Development by Companies, H2 2012 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 27
Comparative Analysis by Late Stage Development, H2 2012 28
Comparative Analysis by Mid Clinical Stage Development, H2 2012 29
Comparative Analysis by Early Clinical Stage Development, H2 2012 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 31
Products under Development by Companies, H2 2012 32
Products under Development by Companies, H2 2012 (Contd..1) 33
Products under Development by Companies, H2 2012 (Contd..2) 34
Products under Development by Companies, H2 2012 (Contd..3) 35
Products under Development by Companies, H2 2012 (Contd..4) 36
Products under Development by Companies, H2 2012 (Contd..5) 37
Products under Investigation by Universities/Institutes, H2 2012 38
Bristol-Myers Squibb Company, H2 2012 39
Bayer HealthCare AG, H2 2012 40
Amgen Inc., H2 2012 41
GlaxoSmithKline plc, H2 2012 42
MedImmune LLC, H2 2012 43
Daichi Sankyo Company, Ltd, H2 2012 44
Stiefel Laboratories, Inc., H2 2012 45
Novartis AG, H2 2012 46
Eisai Co., Ltd., H2 2012 47
Galderma S.A., H2 2012 48
LEO Pharma A/S, H2 2012 49
Nippon Shinyaku Co., Ltd., H2 2012 50
Almirall, S.A., H2 2012 51
NicOx SA, H2 2012 52
Nuvo Research Inc., H2 2012 53
Regeneron Pharmaceuticals, Inc., H2 2012 54
Array BioPharma Inc., H2 2012 55
ProMetic Life Sciences Inc., H2 2012 56
Phytopharm Plc, H2 2012 57
Hanall Pharmaceutical Co., Ltd., H2 2012 58
AnGes MG, Inc., H2 2012 59
Provectus Pharmaceuticals, Inc., H2 2012 60
Summit Corporation plc, H2 2012 61
Proximagen Neuroscience plc., H2 2012 62
R-Tech Ueno, Ltd., H2 2012 63
Fougera, H2 2012 64
Paloma Pharmaceuticals, Inc., H2 2012 65
Morphotek, Inc., H2 2012 66
Asubio Pharmaceuticals, Inc., H2 2012 67
AnaMar Medical AB, H2 2012 68
Palau Pharma S.A, H2 2012 69
Respiratoriuss AB, H2 2012 70
MIKA Pharma GmbH, H2 2012 71
CREABILIS Therapeutics S.r.l., H2 2012 72
Anacor Pharmaceuticals, Inc., H2 2012 73
JADO Technologies GmbH., H2 2012 74
IMMD Inc., H2 2012 75
Hawthorn Pharmaceuticals, Inc., H2 2012 76
Oxagen Limited, H2 2012 77
Melior Discovery, Inc., H2 2012 78
Syntrix Biosystems, Inc., H2 2012 79
Deciphera Pharmaceuticals, LLC, H2 2012 80
SARcode Corporation, H2 2012 81
Hygeia Therapeutics, Inc., H2 2012 82
NKT Therapeutics, Inc., H2 2012 83
Wellchem Biotech Inc., H2 2012 84
APEIRON Biologics AG, H2 2012 85
Cutanea Life Sciences, H2 2012 86
Action Pharma A/S, H2 2012 87
SWITCH Biotech LLC, H2 2012 88
Morria Biopharmaceuticals Plc, H2 2012 89
Maruho Co.,Ltd., H2 2012 90
Pharis Biotec GmbH, H2 2012 91
Viromed Co., Ltd., H2 2012 92
Celtic Pharmaceutical Holdings L.P., H2 2012 93
EMS S.A., H2 2012 94
Clarassance, Inc., H2 2012 95
Assessment by Monotherapy Products, H2 2012 96
Assessment by Combination Products, H2 2012 97
Assessment by Stage and Route of Administration, H2 2012 100
Assessment by Stage and Molecule Type, H2 2012 103
Skin Inflammation Therapeutics – Drug Profile Updates 210
Skin Inflammation Therapeutics – Discontinued Products 222
Skin Inflammation Therapeutics – Discontinued Products (Contd..1) 223
Skin Inflammation Therapeutics – Dormant Products 224
Skin Inflammation Therapeutics – Dormant Products (Contd..1) 225
Skin Inflammation Therapeutics – Dormant Products (Contd..2) 226
Skin Inflammation Therapeutics – Dormant Products (Contd..3) 227
Skin Inflammation Therapeutics – Dormant Products (Contd..4) 228
Skin Inflammation Therapeutics – Dormant Products (Contd..5) 229

List of Figures
Number of Products under Development for Skin Inflammation, H2 2012 18
Products under Development for Skin Inflammation – Comparative Analysis, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 26
Late Stage Products, H2 2012 28
Mid Clinical Stage Products, H2 2012 29
Early Clinical Stage Products, H2 2012 30
Discovery and Pre-Clinical Stage Products, H2 2012 31
Assessment by Monotherapy Products, H2 2012 96
Assessment by Combination Products, H2 2012 97
Assessment by Route of Administration, H2 2012 98
Assessment by Stage and Route of Administration, H2 2012 99
Assessment by Molecule Type, H2 2012 101
Assessment by Stage and Molecule Type, H2 2012 102

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2233957/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Skin Inflammation - Pipeline Review, H2 2012
Web Address: http://www.researchandmarkets.com/reports/2233957/
Office Code: SCD2KD6L

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  Mrs  Dr  Miss  Ms  Prof
First Name: ____________________________  Last Name: ____________________________
Email Address: * ______________________________
Job Title: ________________________________
Organisation: _____________________________
Address: __________________________________
City: ____________________________________
Postal / Zip Code: _________________________
Country: __________________________________
Phone Number: ____________________________
Fax Number: ______________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number: 833 130 83
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World